logo
Share SHARE
FONT-SIZE Plus   Neg

Watson Laboratories Files ANDA To Market Nebivolol Hydrochloride Tablets

Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc. (WPI), has filed an Abbreviated New Drug Application with the FDA seeking approval to market Nebivolol Hydrochloride Tablets, the generic version of Forest Laboratories' Bystolic.

Bystolic is a beta-adrenergic blocking agent that is approved for the treatment of hypertension.

Forest Laboratories filed suit against Watson on March 13 in the US District Court of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent.

Watson said it might be the first applicant to file an ANDA for the generic version of Bystolic and if approved it will be entitled to 180 days of generic market exclusivity.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Delta Air Lines Inc. (DAL) pilots, represented by the Air Line Pilots Association International, are picketing on Friday at several airports across the country. The pilots said the picketing was to raise the sense of urgency in ongoing contract negotiations. The negotiations between the pilots... Charter Communications, and its recently acquired subsidiary Time Warner Cable, have been regularly overcharging its consumers to a tune of $7.2 million per year, according to a report from the U.S. Senate's Permanent Subcommittee on Investigations. According to the report, Time Warner Cable over-billed... Popular photo sharing network Instagram is adding a new translation button on its pages, so that the global crowd can read and enjoy the captions and comments given for the photographs uploaded. The new update will be available from next month onward.
comments powered by Disqus
Follow RTT